Actavis launches Docetaxel single vial on patent expiry in major European markets
(Thomson Reuters ONE) -
Reykjavik, Iceland, 29 November 2010 ? Actavis Group, the international generic
pharmaceuticals company, today announced the launch of a Docetaxel single vial,
immediately after the patent expired in major European markets.
The cancer drug was launched by Actavis under its own brand in Germany, the
Netherlands, UK and Sweden, as well as by Medis ? the company's sales division
to third-party clients ? in the UK and Germany.
Actavis has also launched the Docetaxel single vial in Ireland, Finland,
Portugal and Austria which were patent-free. The product will be launched across
Europe - patents permitting - during 2010 and 2011.
Furthermore, Actavis has launched a Docetaxel twin vial in Romania, the Ukraine
and in the Balkans.
Docetaxel is used to treat a range of different cancers including advanced
breast cancer, lung cancer, prostate cancer and stomach cancer. The Docetaxel
single vial is produced by Actavis in 20mg, 80mg and 140mg vial sizes. Docetaxel
Actavis is the generic equivalent of the Taxotere(®) brand product from Sanofi
Aventis.
The brand product, Taxotere® had sales across 29 countries in Europe of
approximately EUR800 million for the 12 months ending 30 June 2010, according to
IMS Health
The Docetaxel single vial is manufactured by Actavis in Romania.
Jonathan Ody, Vice President, Actavis Hospital business Unit:
"Actavis is delighted to be able to bring to the market a high quality single
vial formulation of Docetaxel, the largest oncology product ever to go off
patent in Europe, and we are launching it the day after patent expiry. Actavis
also brings to market the unique 140mg vial size which is designed to be more
convenient and reduce wastage."
Enquiries
Actavis Group
Hjordis Arnadottir
Director - External Communications
Tel: (+354) 840 7476
E-mail:harnadottir(at)actavis.com
About Actavis Group
Actavis is one of the world's leading generic pharmaceutical companies
specializing in the development, manufacture and sale of generic
pharmaceuticals. The company has operations in 40 countries, with 10,000
employees. For further information on Actavis Group, please
visitwww.actavis.com.
Any statements contained in this press release that refer to Actavis' estimated
or anticipated future results or future activities are forward-looking
statements which reflect the Company's current analysis of existing trends,
information and plans. These forward-looking statements are subject to a number
of risks and uncertainties that could cause actual results to differ materially
depending on factors such as the availability of resources, the timing and
effect of regulatory actions, the success of new products, the strength of
competition, the success of research and development issues, unexpected contract
breaches or terminations, exposure to product liability and other lawsuits, the
effect of currency fluctuations and other factors.
[HUG#1466503]
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actavis via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 29.11.2010 - 10:38 Uhr
Sprache: Deutsch
News-ID 49190
Anzahl Zeichen: 3825
contact information:
Town:
Hafnarfjordur
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 225 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actavis launches Docetaxel single vial on patent expiry in major European markets"
steht unter der journalistisch-redaktionellen Verantwortung von
Actavis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
